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ABSTRACT
c-MET and its ligand HGF are frequently overexpressed in colorectal cancer (CRC) 
and increased c-MET levels are found in CRC liver metastases. This study investigated 
the role of the HGF/c-MET axis in regulating migration/invasion in CRC, using pre-
clinical models and clinical samples. Pre-clinically, we found marked upregulation of 
c-MET at both protein and mRNA levels in several invasive CRC cells. Down-regulation 
of c-MET using RNAi suppressed migration/invasion of parental and invasive CRC 
cells. Stimulation of CRC cells with rh-HGF or co-culture with HGF-expressing 
colonic myofibroblasts, resulted in significant increases in their migratory/invasive 
capacity. Importantly, HGF-induced c-MET activation promoted rapid downregulation 
of c-MET protein levels, while the MET transcript remained unaltered. Using RNA  
in situ hybridization (RNA ISH), we further showed that MET mRNA, but not protein 
levels, were significantly upregulated in tumor budding foci at the invasive front of 
a cohort of stage III CRC tumors (p < 0.001). Taken together, we show for the first 
time that transcriptional upregulation of MET is a key molecular event associated 
with CRC invasion and tumor budding. This data also indicates that RNA ISH, but 
not immunohistochemistry, provides a robust methodology to assess MET levels as 
a potential driving force of CRC tumor invasion and metastasis.
INTRODUCTION
Colorectal cancer (CRC) is a major cause of cancer 
related death worldwide, with significant variation in 
prognosis between early and late stage disease. Five year 
overall survival (OS) rates for patients with localised stage 
II disease are as high as 80% following surgery, dropping 
to 40–60% for patients with stage III disease who display 
evidence of tumor invasion and regional lymph node 
metastasis [1]. Tumor budding is defined by the presence 
of individual tumor cells and/or small clusters of cancer 
cells at the invasive front of tumors [2]. Tumor budding at 
the invasive front has long been associated with presence 
of lymph node and distant metastasis, increased risk of 
relapse and is now a well-accepted prognostic factor in 
CRC [3–5]. However, the underlying biology driving the 
distinct prognostic differences between localised tumors 
and those which have developed an increased invasive 
capacity is, as yet, not fully understood at the molecular 
level. 
Recent studies have highlighted the considerable 
intra-tumoral heterogeneity that exists within CRC primary 
tumors. A recent consensus molecular classification of 
stage II/III CRC has identified the poor prognostic CMS 
4 subgroup, characterized by epithelial-mesenchymal 
transition (EMT) and stem-like transcriptional signatures 
[6]. Further interrogation of this CRC subgroup revealed 
the stromal-rich nature of these tumors, particularly the 
presence of fibroblasts, which account for the high levels 
of mesenchymal associated genes expressed within the 
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CMS 4 subtype [7, 8]. These studies indicated that the 
prognostic value of the CMS 4 subtype is inherently 
associated with fibroblast infiltration, and suggested that 
widespread EMT does not occur within the epithelial 
tumor bulk. Other studies have shown that the interaction 
between epithelial cancer cells at the invasive front or 
budding cells with surrounding stromal cells or their 
secreted factors can locally affect Wnt/β-catenin signalling 
within these cells, triggering stemness, EMT and an 
invasive behaviour, suggesting that this pathway may be 
an important driver of the metastatic process and potential 
therapeutic target in budding cells [9–12].
The interplay between cancer associated 
fibroblasts (CAFs) and tumor cells, leading to metabolic 
reprogramming of cancer and stromal cells and activation 
of an EMT and invasive programme, has been described. 
Tumor-derived secreted factors such as TGF-β1, bFGF, 
and IL-6, have been shown to control the activation of 
cancer associated fibroblasts (CAFs), and the proteome/
secretome of these CAFs, including hepatocyte growth 
factor (HGF), has been found to enhance the invasiveness 
of cancer cells [13, 14]. The prognostic and predictive 
value of tumor-infiltrating fibroblasts is not a new concept 
[15–17]. The recent tumor profiling efforts [18, 19] 
have also failed to identify specific epithelial-derived 
factors associated with the extremely small proportion 
of cells undergoing invasion and budding at the invasive 
front. In order to model CRC cell invasion/metastasis, our 
group has developed invasive CRC daughter cells, which 
display stem-like characteristics, an EMT phenotype and 
increased migratory/invasive levels compared to their 
parental counterparts [20, 21].
The receptor tyrosine kinase c-MET (mesenchymal-
epithelial transition factor), encoded by the MET proto-
oncogene, and its cognate high-affinity ligand HGF 
control invasive growth through the coordination of cell 
proliferation, survival, EMT and migration/invasion [22, 
23]. c-MET expression in CRC primary tumors has been 
found to be predictive of local tumor invasion and regional 
lymph node metastasis [24] and higher c-MET levels have 
been found in synchronous CRC liver metastasis compared 
to levels obtained in matched primary tumors [25, 26]. We 
have previously shown that MEK1/2 inhibition-induced 
c-MET activation is an acute mechanism of resistance to 
MEK1/2 inhibitors in RAS and BRAF mutant CRC [27, 
28].
In this study, we show that c-MET protein and 
mRNA levels are significantly increased in our CRC 
invasive models and that treatment with c-MET-specific 
siRNA abrogates migration/invasion of parental and 
invasive CRC cells. We also demonstrate that incubation 
of CRC cells with rh-HGF or co-culture with HGF-
expressing myofibroblasts significantly increases 
migration/invasion and this was associated with rapid 
downregulation of c-MET protein but not mRNA 
levels. Using RNA in situ hybridization (RNA ISH) and 
immunohistochemistry (IHC), we show high MET mRNA 
but not protein levels in tumor budding foci at the invasive 
front of stage III CRC tumors. Taken together, our results 
indicate for the first time that elevated MET mRNA levels 
is associated with increased invasive capacity in vitro 
and the presence of tumor budding in vivo, suggesting 
that c-MET targeted therapies may represent a promising 
strategy to prevent invasion and disease recurrence in 
stage III CRC. 
RESULTS
c-MET is a key regulator of CRC cell invasion 
and migration in vitro
In order to identify molecular drivers of invasion 
and metastasis, we generated preclinical in vitro invasive 
HCT116 and HKH-2 CRC models which display an 
EMT-like invasive phenotype [20, 21]. Initially, we also 
developed invasive cell populations from the LoVo CRC 
cell line, using Matrigel Invasion Chambers. Using the 
XCELLigence real-time cell migration/invasion tracking 
system, we confirmed the invasion/migration rates of 
our invasive models, and found a 35.7-fold, 3.29-fold 
and 27.7-fold increase in migration rates (P < 0.001) and 
6.65-fold, 1.64-fold and 128-fold increase in invasion 
rates (P < 0.001) in invasive HCT116, HKH-2 and LoVo 
cells respectively (Figure 1A). We assessed MET gene 
expression in these invasive models using qRT-PCR 
and found marked upregulated MET mRNA levels in 
the invasive subpopulations compared to their parental 
counterparts (Figure 1B). Increased MET mRNA levels 
were associated with increased c-MET protein levels in 
invasive subpopulations as compared to their matched 
parental cells (Figure 1C). Interestingly, we also observed 
marked increases in c-MET phosphorylation levels at 
kinase domain residues Y1234/1235 in all our invasive cell 
models, indicating that increased kinase activity of the 
receptor was concordant with c-MET overexpression 
(Figure 1C). Quantification of human HGF (h-HGF) 
protein secretion by ELISA illustrated that both parental 
and invasive CRC cell lines did not secrete physiologically 
detectable levels of h-HGF into the culture medium, 
indicating that overexpression and phosphorylation of 
c-MET in invasive cell lines is independent of autocrine-
HGF secretion (Figure 1D). Consistent with this finding, 
we observed no detectable HGF mRNA levels in our CRC 
cell line models (Supplementary Figure S1). 
In order to investigate a potential role for c-MET in 
regulating migration and invasion, we employed different 
siRNA sequences directed against MET in the HCT116, 
HKH-2, LoVo, and DLD-1 parental and invasive CRC 
cells. Using the XCELLigence real-time cell migration 
tracking system, we found that loss of MET gene 
expression resulted in statistically significant attenuation 
of relative migration rate in parental and invasive cell line 
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models, with a 44–92% reduction compared to scrambled 
control (SC)-treated cells (p < 0.001 for all cell line 
models) (Figure 2A and Supplementary Figure S2A). This 
effect was also evident using in vitro Boyden chamber 
assays, where siMET resulted in marked reduced invasion 
in HCT116 and DLD-1 cell lines (Figure 2B). Importantly, 
the decreased migration/invasion rates observed following 
siMET was not due to increased cell death or changes in 
the cell cycle profile (Supplementary Figure S2B).
HGF-mediated activation of c-MET promotes 
CRC cell migration and invasion
We assessed the role of exogenous HGF in 
promoting migration and invasion of CRC cells. In order 
to model the CRC tumor microenvironment (TME), we 
used the normal colonic myofibroblast cell line CCD-
18Co to represent tumor-associated stromal fibroblasts. 
Initial phenotypic characterisation showed that HCT116 
cells displayed a change from an epithelial to an elongated, 
spindle-shaped mesenchymal morphology 24h following 
incubation with conditioned medium derived from CCD-
18Co cells (CCD-18CoCM) (Supplementary Figure S3A). 
Using an indirect co-culture system, we observed marked 
increased migration and invasion of HCT116 and LoVo 
cells following 48h co-culture with CCD-18Co cells 
(Figure 3A). Although incubation of CRC cells with 
CCD-18CoCM for 72h resulted in a 1.2-fold and 1.5-fold 
increased proliferation rates in HCT116 and LoVo cells 
respectively, the increased invasion rates of HCT116 
and LoVo cells when co-cultured with CCD-18Co cells 
occurred already within the first 24h (Supplementary 
Figure S3B). 
In order to identify the signalling mechanism 
which drives increased migration/invasion in our CRC 
models following co-culture with CCD-18Co cells, we 
assessed the phosphorylation status of 42 RTKs using 
a human phospho-RTK array kit. The phospho-RTK 
array images and matched densitometry data showed 
significant increased c-MET tyrosine phosphorylation 
levels in HCT116 (4.67-fold; p < 0.001) and LoVo (91.39-
fold; p < 0.01) cells following 15-minutes incubation 
with CCD-18CoCM compared to the unstimulated cells 
(Figure 3B). We validated our array results by Western 
blotting, using anti- Y1234/1235 c-MET and total c-MET 
antibodies. Phosphorylation of Y1234/1235 c-MET, but not 
total c-MET levels, was markedly increased in HCT116 
and LoVo cells following 15 min incubation with CCD-
18CoCM (Figure  3B). Further data showed significant 
increases in HGF mRNA and protein levels in CCD-
Figure 1: c-MET protein and mRNA levels are highly upregulated in invasive CRC daughter cell lines. BD BioCoat 
Matrigel invasion chambers were used to isolate invasive subpopulations from a panel of CRC cells. (A) Migration and invasion assays of 
invasive subpopulations of HCT116, HKH-2 and LoVo sublines were compared with the parental cells using the quantitative xCELLigence 
system. (B) qRT-PCR assessment of MET gene expression levels in parental and invasive cell models. (C) Western blot analysis of pc-
MET1234/1235 and c-MET protein expression levels in parental (Par) and invasive (Inv) cell models. (D) HGF protein levels in the culture 
media of parental (Par) and invasive (Inv) subpopulations were measured by ELISA [Positive control: CCD-18Co (18Co)]. *= p <  0.05, 
*** = p < 0.001, n.s. = not significant.
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18Co cells compared to levels measured in the HCT116 
cells (Supplementary Figures S1 and S3C), indicating 
that myofibroblast-derived HGF plays a key role in 
c-MET activation and migration/invasion of CRC cells 
following co-culture with CCD-18Co cells. In addition, 
stimulation of HCT116 and LoVo cells with recombinant 
human HGF (rh-HGF) (25 ng/ml) resulted in significant 
increases in migration (p < 0.001) and invasion (p < 
0.001) rates (Figure 4A), confirming the key role of the 
HGF/c-MET axis in mediating CRC cell migration and 
invasion in the context of the TME. siRNA-mediated 
knockdown of MET and neutralisation of HGF using an 
anti-HGF monoclonal antibody was sufficient to abrogate 
the increased migratory/invasive potential of CRC cells 
following co-culture with CCD-18Co cells (Figure 4B 
and 4C).
Recombinant and myofibroblast-derived HGF 
promotes dynamic downregulation of c-MET 
protein levels
In order to assess the effect of HGF stimulation 
on the stability of c-MET protein levels, we performed 
a time-course experiments with rh-HGF treatment in our 
CRC cells. Marked increases in c-METY1234/1235 levels 
were observed in HCT116 and LoVo cell lines, 15 min 
and 1 hour following stimulation with 25ng/ml rh-HGF; 
however at the latter time-point, downregulation of total 
c-MET levels was observed (Figure 5A). Similar results 
were seen following co-culture of HCT116 and LoVo 
cells with CCD-18Co fibroblasts (Figure 5B). In contrast 
to c-MET protein levels, MET mRNA levels remained 
unchanged, 6, 12 or 24 hours following stimulation 
with rh-HGF (Figure 5C). These data highlight that the 
unstable nature of c-MET protein levels is not reflected 
at the transcriptional level, and therefore that MET 
mRNA expression levels may be a more robust readout 
of biological overexpression and dependency on c-MET.
MET transcription, but not protein expression, is 
upregulated in budding CRC cell populations in 
stage III primary CRC tumors
To support the results of our in vitro experiments, 
we examined MET gene and protein expression in situ 
in budding tumor cells at the invasive front using CRC 
clinical tissues. Budding tumor cells at the CRC invasive 
front are potentially exposed to high physiological 
concentrations of stromal-derived paracrine ligands 
through either direct or indirect contact. Using whole face 
sections of primary stage III CRC tumors (Table 1, n=13), 
we performed RNA in situ hybridisation (RNA ISH) 
using a probe specific for MET (Figure 6A). While there 
appeared to be only small fluctuations in transcription 
levels across the entire section, we performed detailed 
examination of multiple regions at the invasive front 
compared to the central tumor. Using a digital pathology 
method (See Materials and Methods) to measure the 
signal intensity, converting signal intensity into a digital 
surrogate measure of single cell transcript levels, we 
found a significant increase in MET transcription in 
budding cells compared to the central tumor regions 
(p < 0.001) (Figure  6A). While there was some variation 
in the baseline transcript levels in the central regions 
between tumors, we consistently observed an increase in 
the transcript levels in budding cells across all 13 tumor 
budding-positive tumors examined, regardless of the 
associated central region transcriptional levels within each 
Figure 2: c-METi reduces migration and invasion of CRC cell lines. (A) CRC cells were transfected with 10nM SC or 10nM 
c-MET siRNA (MET_6) for 24 hours and the effect on migration was determined using the xCELLigence system. Corresponding c-MET 
protein knockdown was confirmed by Western blotting. (B) Qualitative invasion rate assessment was performed following transfection with 
10 nM SC or 10nM c-MET siRNA (MET_6), using Boyden chambers. ***= p < 0.001.
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tumor (p < 0.001) (Figure 6B). The cell-specific source of 
MET expression was confirmed by both molecular analysis 
and pathology-based assessment. Using Haematoxylin 
and Eosin (H&E) evaluation of the whole tissues sections 
and E-Cadherin staining, MET gene expression was 
localised to the epithelial cells (Supplementary Figure 
S4). In addition, bioinformatics assessment of microarray 
profiles obtained from dissociated fresh primary tumors 
(GSE39396), which had been fluorescence activated 
cell sorting (FACS) selected into specific endothelial, 
epithelial, leukocyte and fibroblast populations, confirmed 
that MET gene expression is significantly higher in tumor 
epithelial cells when compared to endothelial cells or 
leukocyte or fibroblast cells within the TME (p < 0.0001) 
(Supplementary Figure S5).
As our in vitro models showed instability of 
c-MET protein following co-culture with CCD-18Co 
cells and stimulation with rh-HGF, we assessed c-MET 
protein levels in our clinical tissues. IHC analysis 
revealed that although differences in basal c-MET 
protein levels could be detected between individual 
tumors, no increased c-MET protein levels were 
observed between the central and budding cells in 
individual tumors (Supplementary Figure S6). 
DISCUSSION
The establishment of metastasis following the 
development of a primary tumor, requires a number 
of well-defined steps, however the molecular factors 
associated with metastatic progression still remain poorly 
understood [29]. Our previous data and other studies have 
identified a role for AXL in cancer cell migration/invasion 
and showed that AXL levels are required for niche 
activation and the first phase of metastatic colonization 
[21, 30]. However, delineation of the key molecular 
drivers of the initial invasive event in CRC tissues 
requires a detailed investigation of single budding cells 
at the invasive front, which will open the way for novel 
and tailored approaches to target metastatic spread and 
increase outcome of patients with early stage CRC.
Using unsupervised classification of gene expression 
profiles, a number of research groups have published 
Figure 3: Myofibroblast-derived HGF promotes migration and invasion of CRC cells. (A) HCT116 and LoVo cell lines 
were indirectly co-cultured with the colon fibroblast cell line CCD-18Co and the effect on both migration and invasion was determined 
using Boyden chambers. (B) Human phospho-receptor tyrosine kinase (pRTK) array in HCT116 and LoVo cells, cultured with or without 
conditioned media from CCD-18Co fibroblast cell line (18Co-CM). Total phosphorylated MET protein levels was further quantified by 
pixel density assessment and Western blotting. *= Reference for normalisation.
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Table 1: Clinico-pathological features of the stage III CRC patient cohort
Patient characteristics N = 13
Age (y)  
   Median 64
   Range 39–73
Gender  
   Male 8 (62%)
   Female 5 (38%)
T Stage  
   pT0 0
   pT1 0
   pT2 0
   pT3 6 (46%)
   pT4a 0
   pT4b 7 (54%)
N Stage  
   N0 0
   N1 9 (69%)
   N2 4 (31%)
M Stage  
   M0 13 (100%)
   M1 0
Staging  
   IIB 0
   IIIA 1 (8%)
   IIIB 8 (61%)
   IIIC 4 (31%)
   IV 0
Tumor Type  
   Adenocarcinoma 12 (92%)
   Mucinous Carcinoma 1 (8%)
Differentiation  
   Well - Moderate 11 (77%)
   Poorly 3 (23%)
Tumor Site  
   Caecum 5 (39%)
   Ascending Colon 2 (15%)
   Transverse Colon 0
   Sigmoid Colon 3 (23%)
   Splenic Flexure 1 (8%)
   Rectum 2 (15%)
Lymphovascular Invasion (LVI)  
   Yes 10 (76%)
   No 3 (24%)
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Extramural Venous Invasion (EMVI)  
   Yes 4 (31%)
   No 9 (69%)
Perineural Invasion (PI)  
   Yes 0
   No 8 (62%)
   Uncertain 5 (38%)
Tumor Budding  
   Yes 13 (100%)
   No 0
Figure 4: Recombinant HGF promotes migration and invasion of CRC cells. (A) Migration and invasion rates of HCT116 
and LoVo cell lines were measured using the xCELLigence system in the absence and presence of 25 ng/ml rh-HGF. (B) Boyden chamber 
assessment of HCT116 migration and invasion, following transfection with 10 nM SC or 10 nM siMET and indirect co-culture with CCD-
18Co cells. (C) Boyden chamber assessment of HCT116 migration and invasion following co-culture with CCD-18Co cells, in the absence 
or presence of anti-HGF neutralising antibody. ***= p < 0.001.
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3–6 molecular subtypes within stage II/III CRC [18, 19, 
31–33]. Recent consensus molecular subtype analysis by 
the CRC Subtyping Consortium (CRCSC) has coalesced 
these independent classification systems into 4 Consensus 
Molecular Subtypes (CMS 1–4) [6]. Of these subgroups, 
the mesenchymal subtype (CMS4) has been associated 
with poor differentiation and the poorest patient outcome. 
Although the initial studies suggested that cancer cells of 
epithelial origin within CMS 4 had acquired mesenchymal 
traits and stem cell-like properties, resulting in increased 
invasion and metastatic spread, more recent studies 
have shown that the distinctive gene expression profiles 
and clinical features of CMS4 are due to their profuse 
stromal cell component [7, 8]. While the latter studies 
argue against a widespread EMT across the entire tumor, 
these studies do not exclude the possibility that individual 
tumor cells may undergo EMT, particularly at the invasion 
front and in budding cells. Indeed, previous studies have 
shown that tumor cells at the invasive front and budding 
cells have a strong nuclear staining pattern for b-catenin, 
which is associated with loss of membranous E-cadherin 
and Ki-67 expression, epithelial and proliferation markers 
respectively [34, 35]. Not surprisingly, high-grade tumor 
budding in CRC has been associated with poor patient 
outcome, pathological invasion, and metastasis to the 
lymph node and liver [4, 5]. Based on the findings from 
our in vitro models, we performed focused single cell 
profiling of individual CRC tumor buds, in order to reveal 
the precise biology associated with the invasive capacity 
of these budding cells. 
Oncogenic deregulation of the HGF/c-MET pathway 
has been reported in a wide range of human cancers, 
including breast [36], ovarian [37], CRC [25], prostate 
[38], pancreatic [39], gastric [40, 41] and non-small cell 
lung carcinoma [42], where it is often associated with 
drug resistance, enhanced migration/invasion, metastasis 
and a poor clinical outcome [41, 43, 44]. The apparent 
overexpression of MET at mRNA and protein levels, using 
qRT-PCR, microarray transcriptional profiling and IHC, 
has been reported by a number of independent groups 
in CRC [24, 26, 45–48], with a recent meta-analysis of 
a number of these studies offering the consensus that 
overexpression of c-MET and HGF occurs at a frequency 
of up to ~78% and ~95% respectively [49]. In addition, 
elevated c-MET expression and/or amplification has 
also been associated with depth of tumor (T) invasion, 
lymphovascular invasion, presence of regional lymph 
node and distant metastatic disease in CRC [24–26, 50]. 
In order to model CRC cell invasion, our group has 
previously developed invasive CRC daughter cells which 
Figure 5: Exogenous HGF results in rapid downregulation of c-MET protein but not MET mRNA levels. A + B. 
Western blot analysis of pMET1234/1235 and MET levels in HCT116 and LoVo cells following stimulation with rh-HGF (A) or incubation 
with conditioned media from CCD-18Co cells (18Co-CM) (B) for 15 minutes, 1, 3, 6, 12 and 24 hours. (C) qRT-PCR quantification of the 
corresponding MET gene expression levels at 6, 12 and 24 hours following culture in the absence or presence of rh-HGF. 
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displayed an EMT-like phenotype and high levels of CD44 
[21]. We now show that c-MET protein and mRNA levels 
are highly expressed in these models and in our newly 
developed invasive CRC daughter cell lines and that siRNA 
mediated knockdown of c-MET potently inhibited migration 
and invasion of parental and invasive CRC cells. We next 
demonstrated that myofibroblast-derived conditioned 
medium can further potentiate migration and invasion of 
CRC cells through HGF-dependent activation of c-MET 
in CRC cells. Importantly, we found that RNAi against 
c-MET and monoclonal antibodies against HGF abrogated 
the increased migratory and/or invasion potential following 
co-culture of CRC cells with colon myofibroblasts. 
Taken together, these studies suggest a key role for HGF-
independent and HGF-dependent activation of c-MET as a 
molecular driver of CRC cell migration/invasion in vitro.
To underpin the results of our in vitro experiments, 
we used a novel RNA ISH approach for single cell analysis 
of tumor budding foci in a cohort of stage III CRC tumor 
samples. These data showed marked upregulated MET 
mRNA expression in budding tumor cells, compared to 
levels obtained in tumor cells within the central tumor, 
regardless of the overall MET mRNA levels in the 
central regions. Although the CRC cases selected for 
this study most likely have different mutational spectra, 
the increased MET gene expression levels in tumor 
budding foci were consistently observed in every CRC 
tumor tissue sample analysed. This finding confirms the 
homogeneous nature of MET gene expression association 
with actively invading cells and tumor buds. Importantly, 
this transcriptional event was not reflected at the protein 
level, as measured by IHC. Previous studies, including 
Figure 6: Budding cells at CRC invasive front harbour increased MET mRNA levels. (A) Representative image of MET 
RNA in situ hybridization (RNA ISH) across a full-face tumor section at low magnification (x1 top left) and higher magnification for 
selected regions (x5, top right). Differential expression of MET mRNA between the central tumor and budding cells at the invasive front 
was observed qualitatively (x20, bottom left) and determined to be significantly different using SpotStudio software analysis (p < 0.001) 
(bottom right). (B) MET mRNA levels at multiple annotated regions of interests were determined using SpotStudio software across all 13 
CRC cases. Mean MET mRNA levels at each region are indicated using paired assessment (left) and group analysis (right).  *** = p < 0.001.
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our own data, have shown that growth factor binding to 
plasma membrane receptor tyrosine kinases, such as the 
Epidermal Growth Factor Receptor (EGFR), EpHA2 and 
c-MET result in rapid internalization and degradation of 
these receptors, providing a mechanism for preventing 
sustained and uncontrolled pathway activation [20, 51]. A 
number of studies, including our current data, have shown 
that c-MET and HGF are detected primarily in epithelial 
cancer cells and stromal cells respectively [52]. These 
data support our hypothesis that the discordance between 
c-MET protein and MET gene expression, detected in 
tumor budding cells, is  a consequence of HGF-dependent 
internalisation and degradation of the c-MET protein, 
as budding tumor cells are likely to be exposed to high 
physiological concentrations of stromal-derived HGF. 
Thus, the widespread adoption of IHC for biomarker 
analysis is clearly not optimal for proteins such as c-MET, 
which undergo rapid internalisation and degradation after 
exposure to stromal-derived factors. 
Previous studies carried out to assess a potential 
prognostic role for c-MET in CRC have shown 
inconsistent results. These discrepant published data 
reflect not only the differences in technical detection 
methodologies used (IHC, qRT-PCR, FISH) but also 
the wide variety and subjective scoring criteria used for 
IHC [26, 53–57]. As MET gene expression is not subject 
to ligand-dependent negative regulation (Figure 5), our 
study also indicates that the use of a transcriptional semi-
quantitative method such as RNA ISH may be a more 
appropriate technology for measuring the prognostic 
significance of c-MET in invasive CRC. A limitation of 
our study was the small sample size of our pilot study, 
and a larger prospective study is planned to assess c-MET 
expression in stage II/III CRC, using both MET RNA ISH 
and IHC analysis of tumor budding foci, invasive front 
and central tumor and correlate with patient outcome. In 
addition, the ongoing phase I/II MErCuRIC clinical trial 
of combined c-MET/MEK1/2 inhibition in RASMT and 
RASWT metastatic CRC with aberrant c-MET expression, 
is assessing MET RNA ISH, IHC and DDISH in CRC liver 
metastasis and its potential as predictive biomarker [58].
The use of a single cell profiling method, such 
as RNA ISH, has allowed us to begin to uncover the 
transcriptional signalling that is associated with early 
invasive CRC. In addition, the cell-specific precision of 
this approach enables accurate delineation of the source 
of the detected transcript. RNA ISH also allows a cell-by-
cell dissection of the detailed biology underpinning tumor 
progression in CRC, which is not routinely possible using 
standard transcriptomics approaches. 
In conclusion, using preclinical CRC models and 
patient tissue samples, we have identified c-MET as a key 
regulator of CRC cell migration and invasion. A variety 
of therapeutic strategies have been developed to target 
the c-MET axis, including monoclonal antibodies and 
both selective and unselective tyrosine kinase inhibitors. 
Our data provide support for the further investigation of 
c-MET as a target in early stage III CRC patients who 
exhibit high MET mRNA levels in budding cells and the 
invasive front. 
MATERIALS AND METHODS
Cell culture
Acquisition, authentication, and culture of HCT116, 
HKH-2, LoVo, and DLD-1 cells has previously been 
described [21]. CCD-18Co cells were purchased from 
American Type Tissue Culture Collection (ATCC), and 
cultured in Eagle’s Minimum Essential Medium (EMEM) 
according to the manufacturers recommendations. All cell 
lines were authenticated (by short tandem repeat (STR)- 
profiling and karyotyping).
Selection of invasive CRC subpopulations
BD BioCoat Matrigel Invasion Chambers 
(BD Biosciences) were used to isolate invasive cell 
subpopulations from CRC cell lines, as described 
previously [21]. In brief, CRC cells were seeded in serum-
free Dulbecco’s Modified Eagle Medium (DMEM) into 
the upper chamber, and allowed to invade for 72–96 hours 
towards chemoattractant (10% serum DMEM) in the lower 
chamber. Invaded cell populations were subsequently sub-
cultured, and termed “invasive”.
In vitro migration and invasion assays
Real-time migration and invasion were assessed in 
real-time using the CIM-plate 16 and the xCELLigence 
system (Roche Applied Sciences, City Country) 
according to the manufacturer’s instructions, and as 
previously described [21]. For classical migration/
invasion assays, Corning Transwell PET migration 
Chambers (Corning) and BD BioCoat Matrigel Invasion 
Chambers (BD Biosciences) were used as described 
previously [20, 21].
siRNA transfections, flow cytometry, western 
blotting, qRT-PCR, ELISA and RTK array 
profiling
Transfections, Flow Cytometry, and Western blot 
analysis have been previously described [21]. Real-time 
quantitative PCR (qRT-PCR) was performed as previously 
described [20, 21]. The Proteome Profiler Human XL 
Cytokine Array Kit (R&D Systems) was used for pRTK array 
profiling, and ImageJ software (Fiji) for quantification. The 
RayBio® Human HGF ELISA kit was used for quantification 
of HGF secretion, as previously described [27].
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Patients and samples for the pilot study
For assessment of c-MET expression at the invasive 
edge and in the central tumor, FFPE primary CRC tumor 
blocks from 99 patients who received adjuvant XELOX 
treatment were obtained (NIB12–0034). From this 
cohort, H&E stained serial whole tissue sections were 
microscopically examined and 13 cases were identified 
having i) a clear central tumor region, incorporating 
neoplastic glands distal from the stroma; ii) an invasive 
front, with a clear tumor-stroma boundary; iii) a 
surrounding stromal region adjacent to the invasive edge; 
iv) evidence of tumor budding.
RNAscope staining and quantification of MET 
mRNA expression 
Sections from the selected 13 FFPE tumor blocks 
were stained for MET mRNA using the RNAscope® 2.0 
HD Detection Kit (Brown) for FFPE Tissues (Advanced 
Cell Diagnostics, Hayward, CA; #310035). Briefly, 
sections were cut at 4 μm, air-dried overnight, baked 
at 60°C for 1 hour, dewaxed, and air-dried before pre-
treatments. For all probes, a standard pre-treatment 
protocol was used. Three RNAscope® probes were 
employed in this study: Homo sapiens MET (Hs-MET) 
(Cat. No. 423101 - sequence region 175–6505), positive 
control probe Homo sapiens ubiquitin C (Hs-UBC) 
(Cat. No. 310041 – sequence region 342–1503), and 
negative control probe dihydrodipicolinate reductase 
(bacterial dapB) (Cat. No. 310043 – sequence region 
139–989). Slides were scanned using an Aperio scanner 
at 40X resolution. Quantification of MET mRNA in 
selected regions of interest (ROI) was performed using 
SpotStudio™ software (Definiens and Advanced Cell 
Diagnostics). ROI’s included i) budding cells at the 
leading edge of the tumor, defined as small clusters of 
five or less cells located in the stroma, which have broken 
away from the epithelial glands at the invasive edge, and 
ii) central tumor regions, defined as epithelial cells with 
glandular morphology located distal to the invasive edge. 
Results for these selected cases were expressed as mean 
number of spots estimated per cell. 
c-MET immunohistochemistry and scoring 
For IHC evaluation of c-MET protein expression, 
the CONFIRM Anti-Total c-MET (SP44) Rabbit 
Monoclonal Primary Antibody (Ventana®, Cat. No. 790–
4430) was used. Sections for IHC were cut at 4 μm on 
a rotary microtome, dried at 37°C overnight, and then 
used for IHC, which was performed on an automated 
immunostainer (Leica Bond-Max, Milton Keynes, UK). 
A validated and optimized in-house protocol was used for 
c-MET IHC. Antigen-binding sites were detected with a 
polymer-based detection system (Bond, Newcastle Upon 
Tyne, UK; cat. no. DS9800). All sections were visualized 
with diaminobenzidine, counterstained with hematoxylin, 
and mounted in DPX. 
Staining reaction for c-MET IHC was graded on a 
4 four-tiered system: 0: no staining or < 10% of tumor 
cells stained at weak intensity, 1+: weak staining in > 
10% of the tumor cells in the region of interest (ROI), 
2+: moderate staining in > 10% of the tumor cells in the 
ROI, 3+: strong staining in > 10% of the tumor cells in the 
ROI. Only cytoplasmic and membranous expression was 
evaluated. 
Gene expression dataset
Gene expression profiles from an independent CRC 
dataset were downloaded from NCBI Gene Expression 
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) 
under accession number GSE39396. GSE39396 contains 
microarray profiles from fresh colorectal specimens where 
Fluorescence Activated Cell Sorting (FACS) selected 
cells into specific endothelial [CD45(+), EPCAM(–), 
CD31(–), FAP(–)], epithelial [CD45(–) EPCAM(+), 
CD31(-), FAP(– )], leukocyte [CD45(–), EPCAM(–), 
CD31(+),FAP(–)] and fibroblast [CD45(–), EPCAM(–), 
CD31(-), FAP(+)] populations. 
Transcriptional analysis
Partek Genomics Suite® 6.6 software (Partek Inc.) 
was used for dataset analysis. The data was uploaded 
and underwent RMA normalisation prior to downstream 
analysis. Expression values for the 4 probesets 
representing MET were selected (203510_PM_at; 211599_
PM_x_at; 213807_PM_x_at; 213816_PM_s_at). For the 
purpose of clustering, the data matrices were standardized 
to the median value of probeset expression. Following 
standardization, 2-dimensional hierarchical clustering 
was performed (samples x probe sets/genes). Hierarchical 
clustering was carried out using Euclidean distance with 
Ward’s linkage method.
Statistical analyses
GraphPad Prism 5 Software (Graphpad.com) was 
used for all statistical tests of in vitro data. Relative 
expression box and whisker data was plotted as median 
probeset values (10% and 90% values indicated by 
whiskers). Additionally, relative qRT-PCR expression, 
cell cycle values and migration/invasion rates were 
also plotted. Unpaired Students t-tests were used to 
determine significance (p < 0.05) of indicated groups. 
ANOVA tests were used to determine statistical 
significance of multiple groups, with Tukey’s post hoc 
correction.
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